Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) – Pipeline Review, H1 2017’, provides in depth analysis on Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Musculoskeletal Disorders, Hematological Disorders, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Metabolic Disorders and Toxicology under development targeting Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30)

The report reviews Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics and enlists all their major and minor projects

The report assesses Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Blueprint Medicines Corp

Daiichi Sankyo Company Ltd

La Jolla Pharmaceutical Company

Oncodesign SA

Tolero Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC

2.7.11.30) - Overview

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC

2.7.11.30) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC

2.7.11.30) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC

2.7.11.30) - Companies Involved in Therapeutics Development

Blueprint Medicines Corp

Daiichi Sankyo Company Ltd

La Jolla Pharmaceutical Company

Oncodesign SA

Tolero Pharmaceuticals Inc

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC

2.7.11.30) - Drug Profiles

Antibody to Antagonize ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipyridamole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJPC-6417 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for fibrodysplasia ossificans progressiva - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for Fibrodysplasia Ossificans Progressiva - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-0184 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC

2.7.11.30) - Dormant Products

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC

2.7.11.30) - Product Development Milestones

Featured News & Press Releases

Nov 15, 2016: Tolero Pharmaceuticals to Present Progress of Anemia Program at the 58th ASH Annual Meeting and Exposition

Dec 07, 2015: Tolero Pharmaceuticals Presents Positive Preclinical Data on Hepcidin Inhibition for the Treatment of Anemia Associated with Chronic Disease

Nov 12, 2015: Tolero Pharmaceuticals Presents Positive Clinical and Preclinical Data on TP-0184 in Leukemia and Anemia at the 57th ASH Annual Meeting and Exposition

Oct 19, 2015: Ember Therapeutics Announce Initial Positive Results From a Phase 2 Trial of BMP-7 in Patients with Moderate Osteoarthritis of the Knee

Aug 18, 2015: La Jolla Pharmaceutical Company Receives Orphan Drug Designation for Two Novel Compounds for Fibrodysplasia Ossificans Progressiva

Jun 16, 2015: Tolero Pharmaceuticals Presents Positive Preclinical Data on Hepcidin Inhibition for the Treatment of Anemia Associated with Chronic Disease

Jun 04, 2015: Tolero Pharmaceuticals to Present Preclinical Pipeline Data On TP-0184 at the 20th Congress of European Hematology Association, EHA

Apr 18, 2013: La Jolla Pharma Receives Orphan Designation From FDA For LJPC-6417

Nov 16, 2011: Hormone That Controls Iron Levels May Be Target for Atherosclerosis Treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Blueprint Medicines Corp, H1 2017

Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Pipeline by La Jolla Pharmaceutical Company, H1 2017

Pipeline by Oncodesign SA, H1 2017

Pipeline by Tolero Pharmaceuticals Inc, H1 2017

Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports